Myeloid Therapeutics

Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company`s cutting-edge in vivo engineering platform is designed to target and activate myeloid cells within solid tumors, promoting enhanced anti-tumor adaptive immunity without requiring ex-vivo cell modification. Their proprietary retrotransposon-mediated gene-insertion technology enables the insertion of larger genetic sequences into the genome, surpassing the limitations of current technologies. Myeloid Therapeutics` mRNA techniques empower myeloid cells to effectively engulf cancer cells, produce anti-cancer agents, encourage adaptive immune responses, and modify the tumor microenvironment, all aimed at improving patient outcomes. Their innovative approach underscores a broader goal to advance cell and gene therapy, integrating disciplines like immunology, genetics, and protein science.